Raed Alhusayen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/721058/publications.pdf

Version: 2024-02-01

39 papers 1,258 citations

16 h-index 395702 33 g-index

41 all docs

41 docs citations

41 times ranked 1448 citing authors

#	Article	IF	Citations
1	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101.	1.2	77
2	Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Journal of the American Academy of Dermatology, 2022, 86, 249-252.	1.2	8
3	Common Dermatologic Disorders in Down Syndrome: Systematic Review. JMIR Dermatology, 2022, 5, e33391.	0.7	2
4	Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox. British Journal of Dermatology, 2022, 186, 768-769.	1.5	3
5	Health Care Utilization for Musculoskeletal Issues DuringÂthe Prediagnosis Period in Psoriatic Arthritis: AÂPopulationâ€Based Study. Arthritis Care and Research, 2021, 73, 680-686.	3.4	12
6	Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. International Journal of Dermatology, 2021, 60, e140-e141.	1.0	18
7	Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. Journal of the American Academy of Dermatology, 2021, 84, 1302-1309.	1.2	21
8	Association between Hidradenitis Suppurativa and Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Dermatology, 2021, 237, 740-747.	2.1	15
9	Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatology, 2021, 237, 479-485.	2.1	5
10	Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. Dermatologic Therapy, 2021, 34, e14851.	1.7	3
11	Overview of Ultrasound Imaging Applications in Dermatology. Journal of Cutaneous Medicine and Surgery, 2021, 25, 521-529.	1.2	25
12	Provision of Dermatologic Care in a Universal Health Care System: A 17-Year Review. Journal of Cutaneous Medicine and Surgery, 2021, 25, 511-520.	1.2	1
13	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology, 2021, 39, 467-478.	1.6	9
14	Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. International Journal of Women's Dermatology, 2021, 7, 346-348.	2.0	3
15	Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. International Journal of Dermatology, 2021, 60, e459-e465.	1.0	14
16	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. Journal of the American Academy of Dermatology, 2021, 85, 1049-1051.	1.2	14
17	Exploring Access to Surgical Interventions for Hidradenitis Suppurativa: Retrospective Population-Based Analysis. JMIR Dermatology, 2021, 4, e31047.	0.7	O
18	Hidradenitis suppurativa and Down syndrome: A systematic review and metaâ€analysis. Pediatric Dermatology, 2020, 37, 1044-1050.	0.9	9

#	Article	IF	Citations
19	Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015. Journal of Rheumatology, 2020, 47, 1644-1651.	2.0	17
20	Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, e81-e82.	1.2	6
21	International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of the American Academy of Dermatology, 2020, 83, e261-e266.	1.2	13
22	Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: Population-based cohort study. American Journal of Transplantation, 2019, 19, 522-531.	4.7	30
23	Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. Journal of Cutaneous Medicine and Surgery, 2019, 23, 537-544.	1.2	18
24	North American clinical management guidelines for hidradenitis suppurativa: AÂpublication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101.	1.2	206
25	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 76-90.	1.2	218
26	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Populationâ€Based Study. Arthritis Care and Research, 2019, 71, 1084-1091.	3.4	68
27	Recent advances in managing and understanding pyoderma gangrenosum. F1000Research, 2019, 8, 2092.	1.6	38
28	Changes in the Practice Patterns and Demographics of Ontario Dermatologists. Journal of Cutaneous Medicine and Surgery, 2018, 22, 390-399.	1.2	6
29	Severe Physical Complications among Survivors of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Drug Safety, 2018, 41, 277-284.	3.2	34
30	Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. Journal of Cutaneous Medicine and Surgery, 2018, 22, 484-487.	1.2	15
31	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2017, 21, 513-524.	1.2	39
32	Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 604-612.	0.4	9
33	The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. Inflammation Research, 2017, 66, 931-945.	4.0	51
34	Risk of Malignancy in Dermatomyositis and Polymyositis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 131-136.	1.2	143
35	Acitretin. Journal of Cutaneous Medicine and Surgery, 2017, 21, 48-53.	1.2	19
36	Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2016, 75, 1059-1062.	1.2	32

RAED ALHUSAYEN

#	Article	IF	CITATIONS
37	Validating the diagnostic code for acne in a tertiary care dermatology centre. European Journal of Dermatology, 2015, 25, 469-471.	0.6	11
38	Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2015, 73, S42-S46.	1.2	24
39	Pharmacologic Interventions for Hidradenitis Suppurativa. American Journal of Clinical Dermatology, 2012, 13, 283-291.	6.7	22